NCT04032418View on ClinicalTrials.gov

Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

August 13, 2020

Primary Completion Date

March 14, 2025

Study Completion Date

March 14, 2026

Conditions

Lung Non-Small Cell Carcinoma

Interventions

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (1)

14263

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors

lead

Roswell Park Cancer Institute

OTHER